Evidence updates
September 19, 2026 · Website v4.3 / Evidence Map v1.1
- Added study-specific dose/context sections to all 17 Signal Cards.
- Added apitegromab and eloralintide cards.
- Updated bimagrumab, semaglutide formulations, direct comparison and survodutide references.
- Published the outcome-scoring rubric and revised scores to match the cited evidence.
- Reconciled the public PDF and expanded source-linked coverage.
Study doses describe research, not treatment instructions. Review dates identify an editorial review, not a guarantee that no newer evidence exists.